Arcturus Therapeutics Holdings (ARCT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.70: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 27%; Below-average business quality; Rich valuation.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.... Read more
Sell if holding. Engine safety override at $17.70: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 27%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Arcturus Therapeutics Holdings
About Arcturus Therapeutics Holdings
Arcturus Therapeutics carries an accumulated deficit of $514.6 million as of December 31, 2025, having generated only limited collaboration and grant revenue and no direct product-sales revenue since inception. Its lead internal programs, ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency, are both in Phase 2 trials, while its only commercialized product, the KOSTAIVE COVID-19 vaccine, sells exclusively in Japan through partners CSL Seqirus and Meiji Seika Pharma. In February 2026, CSL Limited disclosed a roughly $430 million write-down tied to the collaboration.
Arcturus built KOSTAIVE, the world's first approved self-amplifying mRNA (sa-mRNA) vaccine, on its proprietary STARR sa-mRNA and LUNAR lipid-nanoparticle delivery platforms, then licensed global rights for COVID-19, influenza, and three other infectious-disease vaccines exclusively to CSL Seqirus under a December 2022 collaboration agreement, earning upfront payments, milestones, and royalties rather than direct product revenue. KOSTAIVE has been commercialized in Japan since October 2024 through CSL Seqirus's exclusive Japanese partner, Meiji Seika Pharma, and has since won approval in the European Union (February 2025) and the United Kingdom (January 2026), though it has not yet achieved meaningful commercial sales outside Japan. Separately, Arcturus retains full worldwide development and commercialization rights to its two internal rare-disease candidates - ARCT-032 (inhaled, LUNAR-delivered CFTR mRNA for cystic fibrosis) and ARCT-810 (LUNAR-delivered OTC mRNA for ornithine transcarbamylase deficiency) - both of which carry FDA Orphan Drug and Rare Pediatric Disease designations that could yield a priority-review voucher on approval.
Show full overview
A concentration the filing quantifies concretely is Arcturus's near-total dependence on a single commercial partner: CSL Seqirus controls research, manufacturing, and commercialization rights for the entire sa-mRNA vaccine franchise, and CSL Limited's February 2026 half-year results cited declining COVID-19 disease burden and more onerous U.S. regulatory requirements as reasons for its roughly $430 million write-down of the collaboration - a signal from the counterparty itself that the franchise's near-term value has deteriorated. Because Arcturus's only marketed product runs through this one relationship, any move by CSL to renegotiate, scale back, or exit the partnership - including a potential separation of the CSL Seqirus business that the 10-K flags as a distinct risk - would remove Arcturus's sole source of commercial revenue rather than merely shrink it.
From Arcturus Therapeutics Holdings 's most recent 10-K filing, extracted September 6, 2026.
Recent developments
updated 2026-09-17Recent Developments — Arcturus Therapeutics Holdings
Latest news
- NEWS National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Marke — benzinga Sep 11, 2026 negative
Generated 2026-09-17T15:17:06Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.70: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 27%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $16.41. Score 4.1/10, moderate confidence.
Take-profit target: $19.40 (+10.0% upside). Prior stop was $16.41. Stop-loss: $16.41.
Quality below floor (2.4 < 4.0).
Arcturus Therapeutics Holdings trades at a P/E of N/A (forward -4.3). TrendMatrix value score: 3.6/10. Verdict: Sell.
18 analysts cover ARCT with a consensus score of 4.1/5. Average price target: $22.
What does Arcturus Therapeutics Holdings do?Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and...
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.